Tag: Generics
Pharmaceutical Patents, Settlements, Reverse Payments, and Exclusion: Update
John Bigelow, Jul 27, 2012
In the June issue of this Chronicle my fellow contributors and I described a trend in appellate court decisions involving...
Pharmaceutical Patents, Settlements, Reverse Payments, and Exclusion
John Bigelow, Jun 27, 2012
Cases involving pharmaceuticals settlements to patent litigation with so called "reverse payments" or, as the FTC now prefers to call...
Cervantes Sequel: The FTC’s Quest to End Pay-for-Delay Pharma Settlements
Anne Layne-Farrar, Jun 27, 2012
We are drawing close to the thirtieth anniversary of the Drug Price Competition and Patent Term Restoration Act, better known...
Reverse Payment Settlements: Presumptively Bad or Usually Acceptable?
Kyle Musgrove, Richard Ripley, Jun 27, 2012
In April 2012, the Federal Trade Commission ("FTC") suffered yet another rebuke of what FTC Chair Jon Leibowitz...
Federal Trade Commission Rejected in “Reverse Payment” Suit
Kevin Noonan, Jun 27, 2012
The Federal Trade Commission in recent years has identified a practice it considers to be a threat to consumers regarding...
Eleventh Circuit Rejects the Strength of a Patent as a Criterion...
Jodi Lucena-Pichardo, William Rooney, Jun 27, 2012
The Eleventh Circuit's recent decision in Federal Trade Commission v. Watson Pharmaceuticals, Inc. (the "AndroGel" decision) addresses the latest...
Federal Trade Commission Suffers Another Setback in Its Campaign to End...
William Michael, Aidan Synnott, Jun 27, 2012
For over a decade, the Federal Trade Commission has sought, with little success, to end "reverse settlement" payments...
2025: Reverse-Payment Settlements Unleashed
Dec 16, 2010
The year is 2025. For the past two decades, brand-name drug companies have settled infringement lawsuits with generic firms by paying them...
The AZ Judgment: A Green Light for Further Action on Pharma...
Sean-Paul Brankin, Sep 30, 2010
On July 1, 2010, the General Court issued its long awaited judgment in AstraZeneca v Commission, almost five years after...
General Court’s AstraZeneca Judgment Set to Embolden Commission
Patrick Harrison, Kristina Nordlander, Sep 30, 2010
Five years and two weeks is a long time to wait for a judgment on appeal. For many,...
